Guardant Health
Blood test detecting cancer at Stage 1, now converting an FDA milestone into commercial scale. Q2 2026 (July 30): total revenue $335M (+44% YoY), oncology volume +63% to ~104,000 tests, and Shield screening revenue jumped to $53M from $15M a year earlier on ~4.1x volume growth (66,000 vs 16,000 tests); FY26 guidance raised for the second straight quarter to $1.34-1.36B. The May 2026 FDA approval of the next-gen Guardant360 Liquid CDx (100x wider genomic footprint) is now showing up as real volume, not just a regulatory checkbox — all flagship products run on the AI-driven Guardant Smart Platform / InfinityAI, a differentiated moat that compounds with every patient.
Scenarios
10% penetration of colorectal screening-eligible population generates $2B+ annual revenue from single test. MetaSight adds liver fibrosis. Network effects compound as AI learning engine improves sensitivity with every patient.
Exact Sciences (Cologuard) owns significant mindshare. Insurance coverage battles are brutal and slow. Manufacturing quality at volume is operationally complex.
Key Factors to Watch
- ●FDA approval (January 2026) for Guardant360 CDx as BRAF V600E companion diagnostic — direct revenue milestone
- ●Shield test — 210K-225K projected 2026 (2.5x growth from 87K in 2025), $162-174M screening revenue guidance
- ●MetaSight acquisition ($59M) adds liver fibrosis detection — second major TAM
- ●AI learning engine improves sensitivity with every patient — compounding moat
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-08-16 | 8.3 | Very Positive | Score 8.0→8.25 (md 8→9). Q2 2026 (July 30) turned the May FDA approval of next-gen Guardant360 Liquid CDx into commercial scale: Shield volume ~4.1x YoY (66K vs 16K tests), oncology volume +63% to ~104K, total revenue +44%, FY26 guidance raised for the second straight quarter to $1.34-1.36B. The AI-driven Smart Platform/InfinityAI moat is demonstrably compounding, not just promised — md up 1 (are/dr held near ceiling/floor). Stays very_positive. |
| 2026-05-16 | 8.0 | Very Positive | W20 refresh — score holds 8.0. Q1 2026 revenue $302M (+48% YoY), TTM crossed $1B; Shield CRC test volume up 5x YoY in Q1 (~44K tests). InfinityAI platform secured tumor-agnostic regulatory approval in Japan. FY2026 guidance raised to $1.30-1.32B. |
| 2026-04-10 | 8.0 | Very Positive | Score 7.8→8.0 (are 8→9). FDA approval (Jan 2026) for Guardant360 CDx BRAF companion diagnostic + MetaSight acquisition + 28 AACR abstracts + $162-174M screening revenue guidance. Direction positive → very_positive. |
| 2026-03-08 | 7.8 | Positive | Score 7.6→7.8 (formula reweight: sb 0.25→0.15, are 0.20→0.25, md 0.20→0.25, dr 0.20→0.25, aam 0.15→0.10) |
| 2026-03-08 | 7.6 | Positive | Initial assessment from batch 8 research |
Healthcare Peers
Last researched: 2026-08-16
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.